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Ganciclovir (GCV) and acyclovir (ACV) are guanine nucleoside analogues that inhibit lytic herpesvirus
replication. GCV and ACV must be monophosphorylated by virally encoded enzymes to be converted into
nucleotides and incorporated into viral DNA. However, whether GCV and/or ACV phosphorylation in Epstein-
Barr virus (EBV)-infected cells is mediated primarily by the EBV-encoded protein kinase (EBV-PK), the
EBV-encoded thymidine kinase (EBV-TK), or both is controversial. To examine this question, we constructed
EBV mutants containing stop codons in either the EBV-PK or EBV-TK open reading frame and selected for
stable 293T clones latently infected with wild-type EBV or each of the mutant viruses. Cells were induced to the
lytic form of viral replication with a BZLF1 expression vector in the presence and absence of various doses of
GCV and ACV, and infectious viral titers were determined by a green Raji cell assay. As expected, virus
production in wild-type EBV-infected 293T cells was inhibited by both GCV (50% inhibitory concentration
[IC50]  1.5 M) and ACV (IC50  4.1 M). However, the EBV-PK mutant (which replicates as well as the
wild-type (WT) virus in 293T cells) was resistant to both GCV (IC50  19.6 M) and ACV (IC50  36.4 M).
Expression of the EBV-PK protein in trans restored GCV and ACV sensitivity in cells infected with the PK
mutant virus. In contrast, in 293T cells infected with the TK mutant virus, viral replication remained sensitive
to both GCV (IC50  1.2 M) and ACV (IC50  2.8 M), although susceptibility to the thymine nucleoside
analogue, bromodeoxyuridine, was reduced. Thus, EBV-PK but not EBV-TK mediates ACV and GCV
susceptibilities.
Epstein-Barr virus (EBV) is a human herpesvirus that
causes infectious mononucleosis and is associated with a vari-
ety of different human tumors (1, 47, 81). Like all herpesvi-
ruses, EBV can infect cells in either the latent or lytic form
(13). The lytic form of infection is required for horizontal
spread of the virus from cell to cell and from host to host.
During the lytic form of viral replication, EBV uses a virally
encoded DNA polymerase and the oriLyt replication origin to
duplicate its genome (24, 36, 51). The lytic form of EBV
replication can be effectively inhibited in vitro by the guanine
nucleoside analogues, acyclovir (ACV) and ganciclovir (GCV)
(11, 16, 50, 56). Since acyclovir is significantly less toxic than
ganciclovir in patients, acyclovir is generally used to treat dis-
eases associated with lytic EBV infection, such as oral hairy
leukoplakia (3).
GCV and ACV cannot be incorporated into viral or cellular
DNA unless they are phosphorylated and converted into nu-
cleotides (17, 29). Work in other herpesvirus systems has dem-
onstrated that the first step in GCV or ACV phosphorylation
is not performed efficiently by cellular nucleoside kinases but
can be carried out by virally encoded enzymes in cells infected
with various herpesviruses (6, 17, 20, 25, 29, 75). Human her-
pes simplex virus 1 (HSV-1) and HSV-2 encode a viral thymi-
dine kinase (TK) which mediates the first step in GCV and
ACV phosphorylation in virally infected cells (20, 21, 73), and
ACV- and GCV-resistant HSV mutants isolated from patients
commonly have mutations in the viral thymidine kinase gene
(5, 14, 46, 64) and less commonly within the viral DNA poly-
merase gene (61). In contrast, the human cytomegalovirus
(HCMV) does not encode a viral thymidine kinase protein.
Instead, in HCMV-infected cells, the virally encoded protein
kinase (UL97) mediates the first step of GCV phosphorylation
(53, 75) and (albeit much less efficiently) ACV phosphoryla-
tion (76). Once made, the triphosphorylated form of ACV
(and to a lesser extent GCV) is a much better substrate for
herpesvirus-encoded DNA polymerases than cellular DNA
polymerases (17, 29) and thus inhibits viral DNA replication
more effectively than cellular DNA replication.
EBV encodes both a thymidine kinase (EBV-TK, the prod-
uct of the BXLF1 gene) (18, 54) and a protein kinase (EBV-
PK, the product of the BGLF4 gene) (74). EBV-PK is a serine/
threonine protein kinase that shares many of the same
substrates as the UL97 cytomegalovirus (CMV) kinase (28).
Although it has been demonstrated that both GCV and ACV
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are activated and phosphorylated in lytically infected EBV-
positive cells, it remains unclear whether GCV and/or ACV
phosphorylation in EBV-infected cells is mediated primarily by
the viral protein kinase, the viral thymidine kinase, or both.
All studies to date investigating this question have been
performed outside the context of the viral genome, and differ-
ent groups have reported conflicting findings, particularly in
regard to the effects of EBV-TK. For example, one group
reported that EBV-TK (expressed in bacterial lysates) phos-
phorylates GCV and ACV in vitro (GCV more than ACV)
(52), and another group found that overexpression of EBV-TK
in cells enhances GCV phosphorylation and sensitivity to the
cytotoxic effects of GCV and ACV (GCV more than ACV)
(59). In contrast, two other groups reported that EBV-TK
purified from bacterial lysates has a highly restricted substrate
specificity in comparison to HSV-TK and phosphorylates ACV
and GCV extremely poorly if at all (33, 78). Furthermore, in
one of these studies, overexpression of EBV-TK in cells did
not result in GCV phosphorylation or GCV-mediated cell kill-
ing (33).
There is also some evidence that EBV-PK contributes to
GCV activation. 293 cells overexpressing EBV-PK were re-
ported to have enhanced GCV phosphorylation and to be
sensitized to GCV-mediated cell killing (27, 59, 67). However,
overexpression of EBV-TK, but not EBV-PK, was reported to
sensitize cells to killing by penciclovir, a drug that is similar to
acyclovir (59).
Identifying the EBV protein(s) that mediates ACV and/or
GCV sensitivity during normal lytic EBV infection might have
important clinical implications for the treatment of patients
with EBV-associated illnesses. In addition, there is increasing
interest in using the cytotoxic effect of GCV, in combination
with lytic replication-inducing agents, to kill EBV-positive tu-
mor cells (34, 40, 66, 83), since phosphorylated ganciclovir kills
host cells when incorporated into the cellular DNA. The use of
GCV as an anticancer agent requires that drugs be developed
that precisely activate expression of the EBV-encoded pro-
tein(s) mediating GCV phosphorylation in tumor cells.
To address the question of whether EBV-TK and/or
EBV-PK contributes to the ability of GCV and/or ACV to
inhibit lytic EBV replication in the context of the intact EBV
genome, we constructed EBV mutants defective in either
EBV-PK or EBV-TK function and compared the ability of
GCV and ACV to inhibit lytic replication of the mutant virus
versus that of the wild-type (WT) virus in 293T cells. These
studies were made possible by our recent discovery that WT
and PK mutant viruses produce infectious virions with similar
efficiencies in 293T cells (57), even though the PK mutant virus
is highly impaired for virus production in most other cell types
(31, 62). We show here that the EBV-PK mutant but not the
EBV-TK mutant is resistant to the antiviral effects of both
GCV and ACV. These results indicate that the EBV-encoded
protein kinase and not the EBV-encoded thymidine kinase
activates GCV and ACV phosphorylation in cells that are
lytically infected with EBV.
MATERIALS AND METHODS
Cell lines. The 293T cell line is derived from human kidney epithelial cells
transformed with adenovirus E1A and E1B and subsequently infected with
simian virus 40 (SV40) virus and expresses the SV40 large T and small t antigens
(48, 84). 293T cells were cultured in Dulbecco’s modified Eagle medium
(DMEM) with 10% fetal bovine serum (FBS), 100 U of penicillin/ml, and 100 g
of streptomycin/ml. Raji cells (ATCC) were maintained in RPMI 1640 with 10%
FBS and penicillin-streptomycin. All cells were grown at 37°C in a humidified
5%-CO2 incubator.
Chemicals. Ganciclovir (GCV), acyclovir (ACV), and 5-bromo-2-deoxyuri-
dine (BrdU) were purchased from Sigma (St. Louis, MO). GCV was dissolved in
0.1 N HCl at 10 mg/ml as a stock solution. ACV was dissolved in 1 M HCl at 50
mg/ml as a stock solution. BrdU was dissolved in water as a concentration of 10
mg/ml.
Construction of PK and TK mutant viruses. The PK mutant virus was created
by inserting stop codons at residues 1 and 5 in the EBV-PK open reading frame
(in the EBV B95-8 strain of bacterial artificial chromosome [BAC]) as described
in reference 85. The detailed phenotype of this mutant is described in reference
57. The pGS284 shuttle vector (60) and the EBV wild-type BACmid p2089 (19)
were previously described and were gifts from W. Hammerschmidt (German
Research Center for Environment and Health, Munich, Germany). EBV WT
BACmid p2089 contains a hygromycin resistance cassette and expresses green
fluorescent protein (GFP) (for visualization of infected cells). To create the TK
mutant virus, which contains a stop codon inserted at residue 2 in the TK open
reading frame, the wild-type EBV sequence 144208 to 145410, flanking the EBV
TK start site, was PCR amplified using the primers BXLF1-144208 (5-GCGA
GCTCGTGTTCGAAGAGACCAGAAGGCTTACC-3) and BXLF-1-145410
(5-GCTCTAGACAGCGGGAGAGGAGGTTTAGCAGG-3) and cloned into
pSP65 to make pSP65-TKreg. Site-directed mutagenesis was performed accord-
ing to the manufacturer’s protocol (Stratagene) to convert the second amino acid
of EBV-TK to a stop codon using the primers BXLF1-STOP-A-S (5-CTCCTT
TCCTGGAAATCCCTACATGGATCCCACCCGGGGTC-3) and BXLF1-
STOP-S (5-GACCCCGGGTGGGATCCATGTAGGGATTTCCAGGAAAG
GAG-3). The mutated EBV-TK open reading frame was then cut out of pSP65
and ligated into the shuttle vector pGS284 to yield pGS284-TKStop. pGS284-
TKStop in Escherichia coli S17pir was conjugated with the wild-type EBV
BACmid p2089 in E. coli G500, and cointegrates were selected in LB containing
carbenicillin and chloramphenicol. Cultures were then recovered in LB contain-
ing chloramphenicol only and plated on LB plates containing 5% sucrose and
chloramphenicol. Colonies containing the correct mutations were further
screened by DNA sequencing of the EBV-TK region and restriction enzyme
analysis comparing the TKStop BACmid with wild-type BACmid DNA using
BamHI, HindIII, SalI, and EcoRI independent digestions to make certain that
no deletions or rearrangements of the viral genome had occurred.
293T cell clones. 293T cells were transfected with EBV WT BAC, the EBV-PK
stop codon mutant construct (PKmut), or the EBV-TK stop mutant construct
(TKmut) using Lipofectamine 2000 (Invitrogen) as described in the manufac-
turer’s protocol. Selection of stable cell clones carrying the WT, PKmut, and
TKmut BACmids was performed in DMEM medium with 100 g/ml hygromy-
cin. Stable clones were transfected with the BZLF1 and BRLF1 expression
vectors (pSG5-Z and pSG5-R, gifts from S. Diane Hayward) (70) plus a gp110
expression vector (pRK5-BALF4, a gift from H. J. Delecluse) (63) to induce lytic
replication. The supernatant from these cells was then used to infect Raji cells.
The GFP-positive, hygromycin-resistant cell clones that produced the highest
infectious viral titer were chosen for further study; several independent clones
were selected and frozen at early passage for the WT and mutant viruses.
Drug susceptibility assays. 293T-WT, 293T-PKmut, and 293T-TKmut cells
were cotransfected in six-well plates with a BZLF1 expression plasmid (pSG5-Z;
0.5 g/well), a BRLF1 expression plasmid (pSG5-R; 0.5 g/well), and a gp110
expression plasmid (pRK5-BALF4; 0.5 g/well) to induce lytic replication in the
presence or absence of GCV or ACV. In some experiments, 0.5 g of a C-
terminal FLAG-tagged WT EBV-PK expression vector (a gift from Manfred
Marschall) (55) was added to the transfection mix to complement the defect of
293T-PKmut cells. Virus supernatants were harvested and filtered through an
0.8-m filter 2 days after transfection. Viral titers were determined by the green
Raji cell assay (38). Raji cells (4  105 in 1 ml medium/well) were infected in
24-well plates with a serial dilution of virus supernatant. Phorbol-12-myristate-
13-acetate (TPA) (20 ng/ml) and sodium butyrate (3 mM) were added 24 h later.
The next day, the GFP-positive Raji cells were scored using a fluorescence
microscope. The number of green Raji cells per milliliter (GRU/ml) was calcu-
lated to determine the concentration of infectious virus particles. All experi-
ments were performed in duplicate.
Immunoblot analysis. 293T-WT, 293T-PKmut, or 293T-TKmut cells were
transfected with a BZLF1 expression vector in the presence or absence of a
cotransfected EBV-PK expression vector to induce lytic replication. Immuno-
blots were performed as previously described (57). Primary antibodies used were
as follows: anti-Z (mouse; 1:250 [Argene]), anti-EBV diffuse early antigen
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(BMRF1; mouse; 1:250 [Vector Laboratories]), anti-BGLF4 (C-terminal; rabbit;
1:1,000 [Abgent]), anti-EBV-TK antibody (rabbit; 1:2,000) (32), and -actin
antibody (mouse; 1:5,000). After primary antibody incubation, membranes were
washed in 1 phosphate-buffered saline–5% milk–0.1% Tween 20 (PBST) three
times (5 min for each wash) and incubated in horseradish peroxidase secondary
antibody (Thermo Scientific) at a 1:10,000 (antirabbit) or 1:5,000 (antimouse)
dilution. Membranes were then washed with PBST three times (15 min for each
wash) and visualized by enhanced chemiluminescence (ECL) treatment (Pierce)
and exposure to film.
Drug IC50 determinations. 293T-WT, 293T-PKmut, or 293T-TKmut cells were
cotransfected in six-well plates with pSG5-Z (0.5 g/well), pSG5-R (0.5 g/well),
and pRK5-BALF4 (0.5 g/well) to induce lytic replication in the presence or
absence of different doses of GCV or ACV for 48 h. For 293T-WT and 293T-
TKmut cells, the doses of GCV were 0, 0.25 g/ml, 0.5 g/ml, 1 g/ml, 2.5 g/ml,
and 5 g/ml; doses of ACV were 0, 0.5 g/ml, 1 g/ml, 2.5 g/ml, 5 g/ml, and
10 g/ml. For 293T-PKmut cells, the doses of GCV were 0, 1, 2.5, 5, 8, and 10
g/ml; doses of ACV were 0, 5, 10, 25, 30, and 50 g/ml. The green Raji cell assay
was performed as described above to determine the titer of virus in duplicate
transfections. The experiments were repeated twice. The data were analyzed by
using the CurveExpert 1.4 software program to determine the 50% inhibitory
concentration (IC50).
RESULTS
Establishment of 293T cell clones latently infected with WT,
PKmut, and TKmut viruses. EBV mutants containing stop
codon insertions in residues 1 and 5 of the EBV-PK open
reading frame or residue 2 of the EBV-TK open reading frame
(in an EBV B958 strain BACmid construct) were constructed
as described in Materials and Methods and transfected into
293T cells. Stable 293T cell clones with the latent form of EBV
infection were then selected by treating cells with hygromycin
(100 g/ml) for 14 days. Thirty resistant clones for each virus
were subsequently screened for the ability to produce high-
titer virus following BZLF1 transfection as described in Mate-
rials and Methods. Clones which produced high-titer virus
were kept for further experiments and frozen at early passage.
Three different clones from the WT or mutant viruses in 293T
cells were expanded and analyzed. Similar results were ob-
tained with each clone.
To confirm that 293T-PKmut cells do not express EBV-PK,
we examined the level of endogenous EBV-PK expression in
BZLF1/BRLF1-transfected 293T-WT and 293T-PKmut cells.
293T cells with WT EBV infection but not PKmut infection
had detectable EBV-PK expression (Fig. 1A). In addition, the
hyperphosphorylated form of the viral BMRF1 protein, which
is observed only in the presence of EBV-PK (10, 30, 31), was
found in BZLF1/BRLF1-transfected 293T-WT cells but was
not seen in BZLF1/BRLF1-transfected 293T-PKmut cells (Fig.
1B). Cotransfection with an EBV-PK expression vector re-
stored the hyperphosphorylated form of BMRF1 in the PKmut
virus-infected cells (Fig. 1B). This result confirms that 293T-
PKmut cells do not have EBV-PK function.
To confirm that 293T-TKmut cells are unable to express
the EBV-TK protein, we performed immunoblot analysis on
the lysates of BZLF1/BRLF1-transfected 293T-WT and
293T-TKmut cells (Fig. 1C) using an anti-EBV-TK anti-
body. BZLF1/BRLF1 transfection induced EBV-TK and
BMRF1 expression in 293T-WT cells as expected, but the
EBV-TK protein was not detectable in 293T-TKmut cells,
although the BMRF1 protein was induced (Fig. 1C). These
results indicate that the 293T-TKmut cells do not express the
EBV-TK protein.
PKmut and TKmut viruses are not defective for lytic virus
production in 293T cells. The phenotype of the PKmut virus in
293 cells versus 293T cells is described in detail elsewhere (57).
Similar to the results of previous studies, loss of EBV-PK
expression was found to severely impair the ability of PKmut-
infected 293 cells to release infectious viral particles, since
EBV-PK is required for nuclear egress of the virus in this cell
type (31, 62). Somewhat surprisingly, we found that PKmut was
not impaired for release of infectious viral particles following
BZLF1 transfection in 293T cells (Fig. 2). The TKmut virus
also replicated at least as well as WT EBV in 293T cells (Fig.
2). The ability of TKmut to replicate in 293T cells was not
unexpected, since EBV mutants containing foreign gene inser-
tions that should inactivate viral EBV-TK function have al-
ready been described and shown to replicate in tumor cell lines
(58, 72). The unexpected ability of PKmut to produce virus
efficiently in 293T cells allowed us to ask whether PKmut or
TKmut virus is more resistant to ACV or GCV treatment than
WT virus.
TKmut virus remains highly sensitive to ACV. HSV repli-
cation is efficiently inhibited by ACV (IC50  0.45 to 1.47 M)
FIG. 1. Creation of stable 293T cell clones latently infected with
WT, PKmut, and TKmut viruses. (A) 293T cells latently infected with
EBV WT or PKmut viruses were transfected with vector control or
BZLF1 and BRLF1 expression vectors (“Z”) to induce lytic gene
expression, and extracts were analyzed by immunoblotting for EBV-
PK, BZLF1, and -actin. (B) 293T cells latently infected with EBV WT
or PKmut viruses were transfected with vector control or BZLF1 and
BRLF1 expression vectors in the presence or absence of a cotrans-
fected EBV-PK expression vector, as indicated. Extracts were analyzed
by immunoblotting for BZLF1, BMRF1, and -actin. The hyperphos-
phorylated (pp-BMRF1) and phosphorylated (p-BMRF1) forms of the
BMRF1 protein are indicated; the hyperphosphorylated form of
BMRF1 requires expression of EBV-PK (10, 30, 31). (C) 293T cells
infected with WT or TKmut viruses were transfected with vector con-
trol or the BZLF1 (Z) and BRLF1 expression plasmids. Extracts were
prepared and analyzed by immunoblotting for expression of the lytic
EBV proteins, BMRF1, BZLF1, EBV-TK, and cellular -actin.
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(65), and the viral thymidine kinase protein is required for viral
susceptibility to ACV (69). HCMV, which does not have a
virally encoded thymidine kinase, is relatively resistant to the
antiviral effect of ACV (IC50  77  2.1 M) (76). We there-
fore hypothesized that EBV-TK may be required for suscep-
tibility of EBV to ACV. To determine if this is the case,
293T-WT and 293T-TKmut cells were transfected with
BZLF1/BRLF1/gp110 expression vectors to induce lytic repli-
cation in the presence or absence of ACV (25 g/ml). Viral
titers were examined 2 days later using the green Raji cell assay
as described in Methods. Duplicate transfections were per-
formed for each condition, and each experiment was per-
formed at least twice using independently derived WT and
TKmut clones. As shown in Fig. 3A, ACV inhibited replication
of both WT and TKmut virus by approximately 95%. These
results suggest that EBV-TK does not mediate the antiviral
effects of ACV in cells with lytic EBV infection, and they are
consistent with the previous findings that neither highly puri-
fied EBV-TK nor EBV-TK expressed by itself in cells phos-
phorylates ACV (33).
TKmut virus is also highly sensitive to GCV. HSV is sus-
ceptible to both ACV (IC50  0.45 to 1.47 M) (65) and GCV
(IC50  0.45 to 1.3 M) (9), and in both cases this suscepti-
bility is mediated by the virally encoded TK (15, 69). In con-
trast, HCMV is much more susceptible to GCV (IC50  5.1
M) (76) than ACV (IC50  77  2.1 M) (76), and in
HCMV, susceptibility to GCV is mediated by the virally en-
coded UL97 PK (which is a less active enzyme than HSV-TK).
To determine if EBV susceptibility to the antiviral effects of
GCV requires EBV-TK, 293T-WT and 293T-TKmut cells were
transfected with the BZLF1/BRLF1/gp110 expression vectors
to induce lytic replication in the presence or absence of GCV
(5 g/ml), and the virus titer was determined. As shown in Fig.
3B, GCV (5 g/ml) inhibited replication of WT and TK mutant
virus to similar degrees (approximately 95% at the dosage
used) in 293T-WT and 293T-TKmut cells. These results indi-
cate that EBV-TK is not required for GCV to inhibit the lytic
form of EBV replication.
TKmut virus has reduced susceptibility to BrdU. 5-Bro-
modeoxyuridine (BrdU) is a nucleoside analog of thymidine
that has antiviral properties and is a known substrate of
EBV-TK (33). To study the sensitivity of the EBV-TK mutant
to BrdU, 293T-WT and 293T-TKmut cells were induced into
lytic infection in the presence or absence of different doses of
BrdU. As shown in Fig. 3C, BrdU inhibited virus production in
293T-WT cells in a dose-dependent manner, and TKmut was
FIG. 2. The PKmut and TKmut viruses are not defective for viral
production in 293T cells. (A) 293T cells infected with WT, PKmut, or
TKmut viruses were transfected with the BZLF1, BRLF1, and gp110
expression vectors to induce lytic infection. Viral titers were quanti-
tated by infecting Raji cells with various amounts of the supernatant
72 h posttransfection and counting the number of GFP-positive Raji
cells using a fluorescence microscope. The number of GFP Raji cells
per ml (GRU/ml) is shown. Results from three independent experi-
ments are shown. (B) Extracts from the 293T cells used to create virus
for panel A were immunoblotted with antibodies against BZLF1 and
-actin.
FIG. 3. TKmut has sensitivities to GCV and ACV similar to those
of WT EBV. 293T cells infected with WT EBV or TKmut EBV were
transfected with BZLF1/BRLF1/gp110 expression vectors to induce
lytic replication in the presence or absence of acyclovir (25 g/ml)
(A) or GCV (5 g/ml) (B). Viral titer and viral replication were
examined 48 h later as described in the legend for Fig. 2. The average
viral titer produced by the 293T WT and TKmut cells in the absence of
drug is set as 100% for each cell line ( standard deviation). (C) 293T
cells infected with WT EBV or TKmut virus were transfected with
BZLF1/BRLF1/gp110 expression vectors to induce lytic replication in
the presence or absence of different concentrations of BrdU (10, 5, or
1 g/ml) for 48 h. Viral titers were quantitated as described in the
legend for Fig. 2. The average viral titer produced by the 293T WT and
TKmut cells in the absence of drug is set as 100% for each cell line (
standard deviation).
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less susceptible than the WT virus to the antiviral effect of
low-dose BrdU. For example, BrdU at a dose of 1 g/ml
inhibited WT virus replication by 76% but inhibited TKmut
virus replication by only 26%. These results indicate that the
EBV TKmut virus is partially resistant to BrdU-inhibited virus
replication. The ability of BrdU to prevent viral replication of
TKmut at higher doses likely reflects the cellular toxicity of this
drug, which is also a substrate for human TK1.
PKmut virus has reduced susceptibility to ACV and GCV.
To determine if PKmut virus has reduced susceptibility to
either GCV or ACV, 293T cells infected with WT or PKmut
viruses were induced into lytic infection as described previously
and treated with either no drug or increasing amounts of GCV
and ACV. As shown in Fig. 4A, the PKmut virus was much
more resistant to GCV than the WT virus. For example, while
GCV at the 5-g/ml dose inhibited WT virus replication by
95%, it inhibited replication of the PKmut virus by only 38%
(Fig. 4A). PKmut was also found to be much less susceptible
than the WT virus to the antiviral effects of ACV (Fig. 4B).
While the 25-g/ml dose of ACV inhibited WT virus replica-
tion by 93%, it inhibited the replication of the PKmut virus by
only 52%. Similar results were obtained using independently
derived clones of the PKmut virus (data not shown).
GCV and ACV IC50s for PKmut virus are much higher than
IC50s for WT EBV. To quantitate more precisely the relative
sensitivities of the WT versus PKmut viruses to ACV and
GCV, we repeated the viral titer studies (in duplicate) using a
wider spectrum of drug concentrations and calculated the con-
centration for each drug that inhibited viral replication by 50%
(IC50) as measured by the green Raji cell assay in cells infected
with the WT, PKmut, and TKmut viruses. The results of these
studies are shown in Table 1. In similarity to previously re-
ported values (11, 56, 71, 86), we found that ACV has an IC50
for WT EBV of 4.1 M (0.92 g/ml), while GCV is more
potent, with an IC50 of 1.5 M (0.39 g/ml). In contrast, we
found that ACV has an IC50 of 36.4 M (8.19 g/ml) for the
PKmut virus, and GCV has an IC50 of 19.6 M (5 g/ml). The
IC50s of ACV and GCV were actually lower for the TKmut
virus than for the WT virus, further confirming that EBV-TK
is not required for antiviral susceptibility of EBV to either
ACV or GCV.
Expression of the EBV-PK protein in trans rescues antiviral
susceptibility of the PKmut virus to ACV and GCV. The find-
ing that PKmut-infected 293T cells are much less susceptible to
both GCV- and ACV-mediated inhibition of EBV replication
strongly implies that EBV-PK is required for activation of
these nucleoside analogues. To further confirm this, 293T-
PKmut cells were transfected with BZLF1/BRLF1/gp110 ex-
pression vectors in the presence or absence of an EBV-PK
expression vector. Cells were treated with GCV or ACV or left
untreated, and viral titers were determined. As shown in Fig.
5A, when the EBV-PK protein was expressed in trans, suppres-
sion of PKmut viral replication by GCV (5 g/ml) was in-
creased from 40% to 98% (similar to the level occurring in
cells infected with WT EBV). Likewise, suppression of PKmut
viral replication by ACV (25 g/ml) was increased from 73% to
99% in the presence of cotransfected EBV-PK. These results
confirm that the inability of ACV and GCV to efficiently sup-
press viral replication of the PKmut virus is due specifically to
the loss of EBV-PK expression and not some other (uninten-
tional) alteration in the EBV genome or 293T cell clones.
ACV and GCV have little cellular toxicity in 293T cells at
doses which efficiently inhibit WT virus replication. Phosphor-
ylated GCV (and to a much lesser extent phosphorylated
ACV) can be incorporated by cellular DNA polymerase into
the host cell DNA, resulting in cell death (68). A theoretical
possibility is that the major antiviral effect of these drugs is me-
diated through nonspecific cellular toxicity rather than inhibition
of viral replication per se. To further examine this, 293T EBV-
negative cells were transfected with BZLF1, BRLF1, and gp110
and treated with different doses of GCV or ACV, and the viability
of cells was determined by trypan blue staining 2 days later.
Compared to the solvent control, neither GCV nor ACV treat-
ment had an obvious effect on 293T cell viability at the doses used
to inhibit viral replication in these short-term assays (Fig. 6A
and B).








EBV WT 1.5 (0.4) 4.1 (0.9)
EBV PKmut 19.6 (5.0) 36.4 (8.2)
EBV TKmut 1.2 (0.3) 2.8 (0.6)
FIG. 4. PKmut has reduced susceptibility to acyclovir and ganciclo-
vir compared to WT EBV. 293T cells infected with WT EBV or PKmut
EBV were transfected with BZLF1/BRLF1/gp110 expression vectors
to induce lytic replication. Following transfection, cells were treated
with no drug or different doses of GCV (10, 8, or 5 g/ml) (A) or ACV
(50, 25, or 10 g/ml) (B) for 48 h. Viral titers were examined 48 h later.
The average viral titer produced by the 293T WT and PKmut cells in
the absence of drug is set as 100% for each cell line ( standard
deviation). Results from two independent experiments are shown.
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DISCUSSION
Although GCV and ACV both inhibit the lytic form of EBV
replication in vitro and have been used to treat EBV infection
in patients, it has remained unclear exactly how these drugs are
converted to their active forms in lytically replicating EBV-
infected cells. The conversion of these two nucleoside ana-
logues to their monophosphorylated forms, which is the rate-
limiting first step in their activation, is performed by the viral
thymidine kinase in HSV-infected cells (20) but mediated by
the viral protein kinase (UL97) in HCMV-infected cells (53,
75). Whereas HSV-1 TK is a polynucleoside kinase, UL97 is
not known to be a nucleoside kinase at all, although it phos-
phorylates the acyclic purine analogs ACV and GCV. ACV
and GCV are then subsequently further phosphorylated by
cellular enzymes to become nucleotide triphosphates, which
inhibit viral DNA polymerase-mediated viral DNA replication
both as competitive alternative substrates for GTP and (in the
case of ACV) as a DNA chain terminator (17, 29). Since EBV
encodes both a viral thymidine kinase and a viral protein ki-
nase (homologous to UL97), one or both of these viral proteins
might potentially be required for ACV and/or GCV activity
against EBV. In this paper, we used a genetic approach to
inhibit expression of either EBV-TK or EBV-PK in cells with
lytic EBV infection and determined whether either protein is
required for ACV and/or GCV antiviral activity. Our results
show that EBV-PK but not the EBV-TK is required for the
antiviral effects of both ACV and GCV against EBV.
The conflicting reports about the substrate specificity of
EBV-TK with regard to GCV and ACV (33, 52, 59, 78) have
led to confusion in the field about whether EBV-TK and/or
EBV-PK mediates ACV and/or GCV sensitivity in EBV-in-
fected cells. We have demonstrated here that loss of EBV-TK
activity in the context of the intact EBV genome does not in
any way impair the ability of the virus to respond to either
ACV or GCV (in fact, the IC50s of both ACV and GCV are
slightly lower in cells infected with the TKmut virus than in
cells infected with the WT virus). Thus, EBV-TK is certainly
not required for either ACV or GCV activation in cells with
lytic EBV infection. One potential explanation for this result is
that both EBV-TK and EBV-PK independently induce enough
ACV and GCV phosphorylation in EBV-infected cells that
loss of either viral protein alone does not affect ACV/GCV
susceptibility. However, this possibility is made unlikely by the
finding that cells infected with EBV PKmut (which can still
express EBV-TK at a normal level) are highly resistant to ACV
and GCV. Nevertheless, since EBV-TK and EBV-PK have
been reported to directly interact in yeast two-hybrid assays
(8), consistent with the observation that EBV-TK is a substrate
of EBV-PK (87), it remains theoretically possible that only a
PK-phosphorylated form of EBV-TK can enhance ACV/GCV
phosphorylation in cells, since EBV TK phosphorylated by
cellular enzymes is without activity (33; J. D. Fingeroth, un-
published data).
Although TKmut did not show enhanced resistance to ACV/
GCV (consistent with a previous report that GCV and ACV
are not substrates for EBV-TK [33]), it did confer some sus-
ceptibility to the antiviral effect of the thymidine analogue,
BrdU, a known substrate of EBV-TK. These results indicate
that as previously suggested, thymidine nucleoside analogs
(rather than guanine nucleoside analogues, such as ACV/
GCV) may prove useful as anti-EBV drugs that take advantage
of the EBV-TK activity (33). If so, EBV isolates that become
resistant to ACV/GCV may not necessarily be resistant to
FIG. 6. GCV and ACV are not toxic to 293T cells at the doses used
to inhibit EBV replication. 293T EBV-negative cells were transfected
with BZLF1/BRLF1/gp110 expression vectors and then treated with
no drug or different doses of GCV (A) or ACV (B). Forty-eight hours
later, cells were stained with trypan blue. The percentage of viable cells
without drug treatment is set as 100%.
FIG. 5. Expression of EBV-PK in trans restores susceptibility of
PKmut to ganciclovir and acyclovir. 293T cells infected with WT or
PKmut viruses were transfected with BZLF1/BRLF1/gp110 expression
vectors to induce lytic replication in the presence or absence of a
cotransfected EBV-PK expression vector, as indicated. Following
transfection, cells were treated with no drug or GCV (5 g/ml) (A) or
ACV (25 g/ml) (B) for 48 h, and viral titers were quantitated. The
average viral titer produced for each transfection condition in the
absence of drug is set as 100% for each cell line ( standard devia-
tion). The average viral titer of cells treated with GCV or ACV is
normalized to the average viral titer of cells in the absence of drug.
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thymidine nucleoside analogues, and the antiviral effects of the
guanine nucleoside analogues and the thymidine nucleoside
analogues together might prove synergistic for EBV and de-
crease the likelihood that resistance develops.
Our results here also suggest that the EBV-encoded serine/
threonine protein kinase, like the HCMV UL97 kinase, in-
duces enough GCV phosphorylation when expressed at a nor-
mal level in lytically infected cells to be clinically useful.
Although the HCMV UL97 kinase is generally not thought to
phosphorylate ACV efficiently enough for this drug to be used
for treatment of HCMV infection in patients, ACV is currently
considered by some to be the treatment of choice for lytic EBV
infection in humans (37). Notably, we found that it is EBV-PK,
and not EBV-TK, which mediates the susceptibility of EBV to
ACV. This result suggests that either EBV-PK phosphorylates
ACV more efficiently than the HCMV UL97 kinase or EBV
lytic replication is better inhibited than HCMV replication by
very low levels of triphosphorylated ACV. A head-to-head
comparison will clarify this issue.
Although EBV-PK has a relatively low sequence homology
with UL97, EBV-PK can partially complement a UL97 defect
in the HCMV genome (67), and EBV-PK and HCMV UL97
may share many similar functions during lytic viral replication.
The CMV UL97 kinase and EBV-PK are both required for
nuclear egress of the viruses in most cell lines (35, 62), and
shared cellular substrates of these two kinases include nuclear
lamin A/C (35, 49), cellular elongation factor 1	 (42–44), and
pRB (39; C. V. Kuny, K. Chinchilla, M. Culbertson, and R. F.
Kalejta, submitted for publication). The unusual ability of the
EBV PKmut virus to efficiently produce infectious viral parti-
cles in 293T cells allowed us to study the role of EBV-PK in
mediating ACV/GCV susceptibility. As reported in another
article, we found that both the large and small forms of the
SV40 T antigens contribute to the rescue of the PKmut virus in
293T cells (57). Similarly, another group recently reported that
an HCMV mutant unable to express the UL97 kinase can be
partially rescued by the human papillomavirus E7 viral protein
(41). Interestingly, this paper also showed that the antiviral
effect of maribavir (a drug which inhibits UL97 kinase activity)
(7) is highly attenuated in the presence of E7 (41). Since
maribavir has also been reported to inhibit lytic EBV replica-
tion in some cell types (26, 30), it will obviously be of interest
to determine if the PKmut virus is resistant to this drug in cells
(such as 293T cells) where it is able to replicate.
Our results, as well as those of previous studies (45), also
raise the question of whether GCV might be a more effective
drug than ACV for treating lytic EBV infection in patients. We
found that the IC50 of ACV for WT EBV was 4.1 M, while
the IC50 of GCV was 1.5 M. Previous studies using Southern
blot methods to measure the amount of lytic EBV viral repli-
cation also reported that the IC50 of ACV for WT EBV is
considerably higher (7 to 10 M) (71, 86) than the IC50 of
GCV (found to be 1.0 M) (11, 56). The definition of in vitro
resistance of HSV isolates to ACV has varied in the literature
from 4.4 to 13.2 M, according to the method selected and
various other factors (14, 22, 23). The IC50 for the EBV-PK
mutant virus of acyclovir (36.4 M) would clearly categorize it
as resistant to ACV. Nevertheless, the relatively high IC50 of
ACV for WT EBV, although considerably less than that for
HCMV (77  2.1 M), is much higher than that for HSV
(IC50  0.45 to 1.47 M), raising the possibility that oral ACV
might be only marginally active against lytic EBV infection in
patients, particularly since the reported peak ACV serum level
in patients receiving an 800-mg dose of oral acyclovir is only 7
M (37).
In the case of GCV, the reported peak serum level of drug
following a dose of oral valganciclovir (900 mg) is 23 to 26 M
(37). HCMV isolates are considered to be GCV sensitive at
IC50s of 
6 M (12). Although the IC50 of GCV for WT EBV
is clearly within the range predicted for GCV susceptibility in
patients, the high IC50 of the PKmut EBV virus (19.6 M)
suggests that this mutant would be resistant to GCV therapy in
patients.
A study directly comparing the ability of ACV versus that of
GCV to treat lytic EBV infection in humans has not been
performed. Interestingly, in most studies, ACV treatment has
not been found to benefit patients with infectious mononucle-
osis (IM) (77). In a number of these studies (2, 79, 80), the
peak level of ACV achieved in the serum was likely less than
the IC50 for EBV (since patients received doses of 600 to 800
mg orally five times per day), which could possibly explain the
lack of clinical benefit in these studies. Nevertheless, the lack
of clinical benefit from oral ACV treatment in patients with IM
may reflect not only the relatively low susceptibility of EBV to
this drug, as well as the low oral bioavailability of ACV, but the
fact that many of the symptoms of IM are mediated by the host
immune response to virally infected cells with the latent form
of infection. We predict that either oral valacyclovir therapy,
which results in much higher serum levels of acyclovir (up to 22
M after a dose of 1,000 mg), or oral valganciclovir therapy
would be considerably more effective than oral acyclovir for
treating lytic EBV infection in patients in circumstances where
it is indicated. A small study using valacyclovir to treat patients
with IM suggested that it may improve clinical symptoms (4).
Valacyclovir was reported to effectively treat most cases of oral
hairy leukoplakia (a lytic EBV infection on the tongue that
occurs in immunosuppressed patients), although a few cases
were resistant to this drug (82). Our results suggest that a
clinical study comparing the efficacy of valganciclovir with that
of valacyclovir for treating patients who are severely ill with
uncontrolled IM or who have unusual complications of pri-
mary EBV infection, such as viral meningoencephalitis, may be
warranted. Nevertheless, in patients with less-severe forms of
IM, antiviral therapy is probably not indicated.
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